LENZ Therapeutics (LENZ) has submitted a Marketing Authorization Application to the United Kingdoms Medicines and Healthcare products Regulatory Agency for the review and approval of VIZZ 1.44%, the first aceclidine-based eye drop for the treatment of presbyopia in adults. The company noted that the submission of the MAA in the United Kingdom represents the sixth ex-U.S. regulatory submission for VIZZ. It received FDA approval in July 2025.
The MAA submission is supported by positive data from three randomized, double-masked, controlled Phase 3 studies conducted in the United States.
In pre-market trading on NasdaqGS, LENZ shares are down 2.8 percent to $9.89.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.